Acalabrutinib, marketed under the brand name Acaluxen 100mg, is a breakthrough medication used in the treatment of specific Blood Cancer therapy, including mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL). As a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, Acalabrutinib works by blocking the activity of BTK, a protein that contributes to the growth and survival of cancer cells. This…
Ibrucent 140 mg (Ibrutinib) is an innovative oral medication used to treat specific types of blood cancers, including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrucent, is a Bruton’s Tyrosine Kinase (BTK) inhibitor. This targeted therapy blocks the activity of BTK proteins, which are crucial for the growth and survival…
Ibrutix 140mg (Ibrutinib) is a breakthrough oral medication used for the treatment of specific blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström's Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrutix, is a targeted therapy that works by inhibiting Bruton's Tyrosine Kinase (BTK), a protein essential for the growth and survival of cancerous B-cells. By…
